Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07994525 · 1 trial · 2 indications
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0), timing, seriousness, and relatedness of adverse events (AEs)
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs
Occurrence of DLTs as defined by the protocol
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings
Safety, and preliminary anti-tumor activity
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | Monotherapy Dose Expansion |
| Part 2 | EXPERIMENTAL | Monotherapy Dose Escalation |
| Name | Type | Description |
|---|---|---|
| PF-07994525 | DRUG | Oral administration |
| Midazolam | DRUG | Oral administration |
Inclusion Criteria: * Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent. * Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014) Measurable disease based on IMWG criteria as defined ...
PF-07994525 is an investigational small molecule being developed for the treatment of advanced malignancies, including advanced cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PF-07994525 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PF-07994525 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied in an open-label, controlled trial for advanced malignancies.
PF-07994525 is being evaluated in a Phase 1 clinical trial with the identifier NCT07426757. This open-label study is recruiting participants with advanced malignancies or advanced cancer in the United States and Canada, with a target enrollment of 120 participants aged 18 years and older.
No alternative names for PF-07994525 have been disclosed. The drug is identified solely by its development code PF-07994525 in clinical trial registries and by the sponsor, Pfizer, Inc.